close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ardelyx, Inc. - Common Stock (NQ:ARDX)

2.880 -0.110 (-3.68%)
Delayed Quote Updated: 4:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ardelyx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
News headline image
ARDX Shareholder Alert: Ardelyx, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky
From Levi &amp; Korsinsky, LLP
Via ACCESS Newswire
News headline image
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Ardelyx: 3 Key Takeaways for Long-Term Investors ↗
Doubling the field reimbursement team targets prior authorization friction, a hurdle that can stall prescriptions even after demand is established. 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Ardelyx (ARDX) Q3 2026 Earnings Call Transcript ↗
Patient awareness push and IBSRELA sales growth both gained momentum this quarter. 
Via The Motley Fool
Topics Earnings Economy Intellectual Property
Ardelyx (NASDAQ:ARDX) Q3 2026: Breakeven EPS, Revenue Miss, Guidance Held ↗
Via Chartmill
News headline image
Kaplan Fox Deadline Alert: Ardelyx, Inc. (NASDAQ: ARDX) Investors Have Until November 16, 2026 to Seek a Lead Plaintiff Role
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
ARDELYX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
What Ardelyx (ARDX) Said on Its Q3 Earnings Call ↗
Ardelyx (NASDAQ:ARDX) reported third-quarter product revenue of $125.5 million, up 19% from the prior-year period, as growth in its IBS-C treatment IBSRELA offset more modest revenue growth for... 
Via MarketBeat
Topics Earnings
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines – ARDX
From Pomerantz LLP
Via GlobeNewswire
After-Hours Stock Movers: Nov. 3 Gainers and Losers ↗
Via Chartmill
News headline image
Ardelyx Reports Third Quarter 2026 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
ARDX UPCOMING DEADLINE: SueWallSt Alerts Ardelyx, Inc. Stockholders of Securities Class Action - Contact the Firm
Time-Sensitive: Allegations focus on Ardelyx's representations that its patient-access strategy was working, while more stringent prior authorization and step edit requirements were allegedly slowing... 
From SueWallSt
Via GlobeNewswire
News headline image
Ardelyx Completes Enrollment in Phase 3 ACCEL Clinical Trial of IBSRELA® (tenapanor) in Adults with Chronic Idiopathic Constipation
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
ARDX Shareholder Alert: Ardelyx, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky
Promise vs. Reality: Ardelyx pointed investors toward $1.75 billion in combined peak sales for IBSRELA and XPHOZAH, while the complaint alleges payer utilization-management barriers were already... 
From Levi & Korsinsky, LLP
Via GlobeNewswire
News headline image
ARDELYX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ARDX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ARDX DEADLINE: Levi & Korsinsky Reminds Ardelyx, Inc. Investors of Upcoming Securities Class Action Deadline
From Levi &amp; Korsinsky, LLP
Via ACCESS Newswire
News headline image
Kaplan Fox Urges Ardelyx, Inc. (NASDAQ: ARDX) Investors to Contact the Firm Before the Deadline on November 16, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines – ARDX
From Pomerantz LLP
Via GlobeNewswire
News headline image
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 16, 2026 in Ardelyx, Inc. Lawsuit - ARDX
Ardelyx's Chief Commercial Officer, Eric Foster, is named as an individual defendant in a securities class action alleging he assured investors the Company's patient-access strategy was working while... 
From SueWallSt
Via GlobeNewswire
News headline image
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
ARDX Stock Drop - Robbins LLP Reminds Investors They May Be Eligible to Lead the Ardelyx, Inc. Class Action Lawsuit
San Diego, California--(Newsfile Corp. - October 26, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or... 
Via Newsfile
Topics Lawsuit
News headline image
Levi & Korsinsky Reminds Ardelyx, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 16, 2026 - ARDX
Ardelyx's chief executive, two successive chief financial officers, and its chief commercial officer are each named as individual defendants in a securities class action alleging they controlled public... 
From Levi & Korsinsky, LLP
Via GlobeNewswire
News headline image
Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines – ARDX
From Pomerantz LLP
Via GlobeNewswire
News headline image
ARDX Deadline Alert: SueWallSt Reminds Ardelyx, Inc. (ARDX) Investors of Securities Class Action Deadline on November 16, 2026
A securities class action chronicles how Ardelyx allegedly reaffirmed billion-dollar sales targets for IBSRELA and XPHOZAH across 19 months while payer prior authorization and step edit barriers were... 
From SueWallSt
Via GlobeNewswire
News headline image
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Ardelyx to Report Third Quarter 2026 Financial Results on November 3, 2026
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
ARDX UPCOMING DEADLINE: Levi & Korsinsky Alerts Ardelyx, Inc. Stockholders of Securities Class Action - Contact the Firm
Time-Sensitive: Allegations focus on Ardelyx's representations that its patient-access strategy was working, while more stringent prior authorization and step edit requirements were allegedly slowing... 
From Levi & Korsinsky, LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.